Of the nine combinations analyzed with our method, the combination of Abraxane® with the BCL2/BCLxL inhibitor ABT-263 was found to induce synergistic pancreatic tumor cell apoptosis, a result which was verified upon systemic administration of these agents in an independent pre-clinical combination study. This evidence concerns the gene BCL2L1 and pancreatic neoplasm.